Literature DB >> 31378263

Transcriptional profiling of a laboratory and clinical Mycobacterium tuberculosis strain suggests respiratory poisoning upon exposure to delamanid.

An Van den Bossche1, Hugo Varet2, Amandine Sury3, Odile Sismeiro4, Rachel Legendre2, Jean-Yves Coppee4, Vanessa Mathys3, Pieter-Jan Ceyssens3.   

Abstract

Tuberculosis (TB) is the most deadly infectious disease worldwide. To reduce TB incidence and counter the spread of multidrug resistant TB, the discovery and characterization of new drugs is essential. In this study, the transcriptional response of two Mycobacterium tuberculosis strains to a pressure of the recently approved delamanid is investigated. Total RNA sequencing revealed that the response to this bicyclic nitroimidazole shows many similarities with pretomanid, an anti-tuberculous drug from the same class. Although delamanid is found to inhibit cell wall synthesis, the expression of genes involved in this process were only mildly affected. In contrast, a clear parallel was found with components that affect aerobic respiration. This demonstrates that, besides the inhibition of cell wall synthesis, respiratory poisoning plays a fundamental role in the bactericidal effect of delamanid. Remarkably, the most highly induced genes comprise poorly characterized genes for which functional characterization might hint to the target molecule(s) of delamanid and its exact mode(s) of action.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Delamanid; Mycobacterium tuberculosis; RNA sequencing; Transcriptomics

Mesh:

Substances:

Year:  2019        PMID: 31378263     DOI: 10.1016/j.tube.2019.05.002

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  6 in total

1.  Whole Genome and Transcriptome Sequencing of Two Multi-Drug Resistant Mycobacterium tuberculosis Strains to Facilitate Illustrating Their Virulence in vivo.

Authors:  Jun Tang; Zhihao Liu; Ya'nan Shi; Lingjun Zhan; Chuan Qin
Journal:  Front Cell Infect Microbiol       Date:  2020-05-15       Impact factor: 5.293

Review 2.  Mycobacterial drug discovery.

Authors:  Katherine A Abrahams; Gurdyal S Besra
Journal:  RSC Med Chem       Date:  2020-11-06

3.  Delamanid or pretomanid? A Solomonic judgement!

Authors:  Saskia E Mudde; Anna M Upton; Anne Lenaerts; Hannelore I Bax; Jurriaan E M De Steenwinkel
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

4.  Impaired Succinate Oxidation Prevents Growth and Influences Drug Susceptibility in Mycobacterium tuberculosis.

Authors:  Cara Adolph; Matthew B McNeil; Gregory M Cook
Journal:  mBio       Date:  2022-07-20       Impact factor: 7.786

5.  Nitric Oxide-Dependent Electron Transport Chain Inhibition by the Cytochrome bc1 Inhibitor and Pretomanid Combination Kills Mycobacterium tuberculosis.

Authors:  Sheng Zeng; Jingran Zhang; Mingwei Sun; Xiaofei Zhang; Gregory M Cook; Tianyu Zhang
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

6.  Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients.

Authors:  Martina L Reichmuth; Rico Hömke; Kathrin Zürcher; Peter Sander; Anchalee Avihingsanon; Jimena Collantes; Chloé Loiseau; Sonia Borrell; Miriam Reinhard; Robert J Wilkinson; Marcel Yotebieng; Lukas Fenner; Erik C Böttger; Sebastien Gagneux; Matthias Egger; Peter M Keller
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.